IL255343B2 - Sprinkle formulations of acamprosate - Google Patents

Sprinkle formulations of acamprosate

Info

Publication number
IL255343B2
IL255343B2 IL255343A IL25534317A IL255343B2 IL 255343 B2 IL255343 B2 IL 255343B2 IL 255343 A IL255343 A IL 255343A IL 25534317 A IL25534317 A IL 25534317A IL 255343 B2 IL255343 B2 IL 255343B2
Authority
IL
Israel
Prior art keywords
pharmaceutical formulation
sprinkles
coating
acamprosate
acamprosate calcium
Prior art date
Application number
IL255343A
Other languages
English (en)
Hebrew (he)
Other versions
IL255343B1 (en
IL255343A0 (en
Original Assignee
Confluence Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Confluence Pharmaceuticals Llc filed Critical Confluence Pharmaceuticals Llc
Publication of IL255343A0 publication Critical patent/IL255343A0/en
Publication of IL255343B1 publication Critical patent/IL255343B1/en
Publication of IL255343B2 publication Critical patent/IL255343B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IL255343A 2015-05-04 2016-05-04 Sprinkle formulations of acamprosate IL255343B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562156842P 2015-05-04 2015-05-04
US201562260161P 2015-11-25 2015-11-25
PCT/US2016/030725 WO2016179252A1 (en) 2015-05-04 2016-05-04 Sprinkle formulations of acamprosate

Publications (3)

Publication Number Publication Date
IL255343A0 IL255343A0 (en) 2017-12-31
IL255343B1 IL255343B1 (en) 2024-06-01
IL255343B2 true IL255343B2 (en) 2024-10-01

Family

ID=57217823

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255343A IL255343B2 (en) 2015-05-04 2016-05-04 Sprinkle formulations of acamprosate

Country Status (10)

Country Link
US (1) US10709668B2 (enExample)
EP (1) EP3291800A4 (enExample)
JP (2) JP7026347B2 (enExample)
KR (1) KR102790656B1 (enExample)
AU (1) AU2016258624B2 (enExample)
HK (1) HK1252003A1 (enExample)
IL (1) IL255343B2 (enExample)
SG (1) SG11201708393UA (enExample)
WO (1) WO2016179252A1 (enExample)
ZA (1) ZA201708037B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107636466B (zh) 2015-02-18 2020-07-21 阿斯顿大学 先兆子痫的诊断性测定和治疗
KR102790656B1 (ko) 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
JP2018526345A (ja) * 2015-08-04 2018-09-13 コンフルーエンス ファーマシューティカルズ，エルエルシー アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
AU2018269557B2 (en) * 2017-05-17 2021-06-03 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
WO2022058989A1 (en) * 2020-09-21 2022-03-24 Sun Pharmaceutical Industries Limited Multi-particulate pharmaceutical composition of quetiapine
US20240382133A1 (en) 2021-09-24 2024-11-21 Sumitomo Bakelite Co., Ltd. Brain wave detection electrode, brain wave measuring device, and brain wave measuring method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20120077878A1 (en) * 2010-09-28 2012-03-29 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
WO2012129551A1 (en) * 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
EP1844769A3 (en) 1998-04-14 2010-02-10 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
EP2167068A2 (en) 2007-07-05 2010-03-31 Inserm-Institut National De La Sante Et De La Recherche Medicale Anticonvulsive pharmaceutical compositions
HRP20150120T1 (hr) 2009-02-12 2015-05-08 Indiana University Research And Technology Corporation Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
HUE038653T2 (hu) 2011-03-01 2018-11-28 Pharnext Neurológiai rendellenességek baclofen és acamprosate alapú terápiája
US9526718B2 (en) 2011-06-28 2016-12-27 Vivozon, Inc. Combination of effective substances causing synergistic effects of multiple targeting and use thereof
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3878445A3 (en) * 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
SG11201606275WA (en) 2014-02-11 2016-08-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
KR102790656B1 (ko) 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20120077878A1 (en) * 2010-09-28 2012-03-29 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
WO2012129551A1 (en) * 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEY NS ET AL., MULTIPARTICULATE DRUG DELIVERY SYSTEMS FOR CONTROLLED RELEASE, 11 September 2008 (2008-09-11) *
STRICKELY R. ET AL.:, PEDIATRIC DRUGS--A REVIEW OF COMMERCIALLY AVAILABLE ORAL FORMULATIONS, 1 May 2008 (2008-05-01) *

Also Published As

Publication number Publication date
SG11201708393UA (en) 2017-11-29
US20190046458A1 (en) 2019-02-14
AU2016258624A1 (en) 2017-11-02
WO2016179252A1 (en) 2016-11-10
EP3291800A1 (en) 2018-03-14
US10709668B2 (en) 2020-07-14
KR102790656B1 (ko) 2025-04-02
AU2016258624B2 (en) 2021-07-29
ZA201708037B (en) 2020-03-25
KR20170142180A (ko) 2017-12-27
JP2018515506A (ja) 2018-06-14
EP3291800A4 (en) 2018-09-26
JP2021155434A (ja) 2021-10-07
HK1252003A1 (zh) 2019-05-10
IL255343B1 (en) 2024-06-01
JP7026347B2 (ja) 2022-02-28
IL255343A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
US10709668B2 (en) Sprinkle formulations of acamprosate
ES2922387T3 (es) Microparticulas recubiertas de liberacion modificada de al menos un principio activo y forma galenica oral que las comprende
Sandeep et al. Immediate drug release dosage form: a review
CZ301259B6 (cs) Farmaceutické soli tramadolu, léciva tyto látky obsahující a jejich použití
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
TR201801726T4 (tr) Rasekadotri̇l ve farmasöti̇k bi̇leşi̇mleri̇.
JP7499539B2 (ja) ホモタウリンおよびその塩の製剤
EP2389155A2 (en) Orally disintegrating tablets for the treatment of pain
CA3062834C (en) Formulations of homotaurines and salts thereof
US20220016074A1 (en) Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
US20240408042A1 (en) Orally disintegrating baclofen compositions and methods of making same
Patel Formulation and evaluation of ranolazine sustained release tablets by hot melt coating technique
US20150238615A1 (en) Denaturants for sympathomimetic amines
Alejandro et al. FORMULATION OF AN ORALLY FAST-DISSOLVING FILM USING DIPHENHYDRAMINE HYDROCHLORIDE AS THE MODEL DRUG BY SOLVENT CASTING METHOD
DIHYDROCHLORIDE Reg. No. 26106506
HK1259508B (zh) 氘代多潘立酮组合物和用於治疗病症的方法
TR201613529A1 (tr) Li̇pi̇t düşürücü etki̇ gösteren farmasöti̇k terki̇pler
TW201323014A (zh) 遮味醫藥組合物